BioXcel completes enrollment for mCGI-S/PEC study; sNDA submission expected Q1 2026

BioXcel Therapeutics, Inc.

Open-label study of ~30 patients evaluating mCGI-S vs PEC scale enrolled on Sept 13, 2025; results due Q4 2025.
sNDA for BXCL501 SERENITY At-Home program planned for Q1 2026, incorporating this and prior Phase 3 safety data.
Raised $37.3M from July 1 to Sept 15, 2025 via ATM ($27.6M) and warrant exercises ($9.7M).
As of Sept 12, 2025, shares outstanding totaled 19,646,801; cash expected to fund operations into Q1 2026.

item 7.01item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.